Literature DB >> 15145908

Primary prevention of cardiovascular disease: managing hypertension and hyperlipidaemia.

F D R Hobbs1.   

Abstract

Cardiovascular medicine has a sound evidence base upon which health professionals can base their interventions to modify risk among the British public. For primary prevention of cardiovascular disease, however, while there is considerable evidence on what to do, data are limited on how the evidence should be implemented in practice. The challenge will be to learn by experience which interventions directed at reducing blood pressure and lipids levels work best in different settings. There is a need to structure care to identify individuals who are at risk. Current targets are explicit and achievable for both hypertension and lipids. Effective treatment is likely to require multiple drug treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15145908      PMCID: PMC1876308          DOI: 10.1136/hrt.2004.037580

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Public perceptions of cardiovascular risk in five European countries: the react survey.

Authors:  L Erhardt; F D R Hobbs
Journal:  Int J Clin Pract       Date:  2002-11       Impact factor: 2.503

2.  Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey.

Authors:  P Primatesta; N R Poulter
Journal:  BMJ       Date:  2000-11-25

3.  Improved hypertension management and control: results from the health survey for England 1998.

Authors:  P Primatesta; M Brookes; N R Poulter
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

4.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study.

Authors:  W M Verschuren; D R Jacobs; B P Bloemberg; D Kromhout; A Menotti; C Aravanis; H Blackburn; R Buzina; A S Dontas; F Fidanza
Journal:  JAMA       Date:  1995-07-12       Impact factor: 56.272

5.  Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

Authors:  M J Martin; S B Hulley; W S Browner; L H Kuller; D Wentworth
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

6.  Diabetes trends in the U.S.: 1990-1998.

Authors:  A H Mokdad; E S Ford; B A Bowman; D E Nelson; M M Engelgau; F Vinicor; J S Marks
Journal:  Diabetes Care       Date:  2000-09       Impact factor: 19.112

7.  Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey.

Authors:  F D Richard Hobbs; Leif Erhardt
Journal:  Fam Pract       Date:  2002-12       Impact factor: 2.267

8.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

9.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

Review 10.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

  10 in total
  1 in total

Review 1.  Antihypertensive properties of plant-based prebiotics.

Authors:  Siok-Koon Yeo; Lay-Gaik Ooi; Ting-Jin Lim; Min-Tze Liong
Journal:  Int J Mol Sci       Date:  2009-08-10       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.